Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05767307
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2023-02-08
Brief Title:
Danish Prostate Cancer Consortium Study-1
Sponsor:
Aarhus University Hospital
Organization:
University of Aarhus
Study Overview
Official Title:
Danish Prostate Cancer Consortium Study-1 DPCC-1 Multicenter Development of Liquid Biopsy Biomarkers for Early Detection of Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DPCC-1
Brief Summary:
The purpose of the study is to investigate if a new promising microRNA-based urine biomarker test for prostate cancer called uCaP is better than the current standard test PSA to identify men who would benefit from an MRI scan of the prostate The study will include 2500 men referred to MRI of the prostate at three major hospital centers in Denmark Aarhus Odense and Herlev and compare the accuracy of uCaP to PSA Based on preliminary data it is expected that uCaP will be 20 better than PSA at identifying treatment-requiring cancer Hence uCaP could help to better pre-select men for MRI and thereby reduce unnecessary MRI scans unnecessary prostate biopsies as well as overdiagnosis and overtreatment of indolent PCs while maintaining high sensitivity for aggressive PC that needs early detection and early treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None